[Problems and future perspectives in the treatment of Parkinson's disease].
The most prominent neuropathological lesions in Parkinson's disease have been found in the substantia nigra. The neurochemical alterations are numerous; the most prominent one is the imbalance between acetylcholine and dopamine, the latter transmitter being deficient. Up to now the striato-nigral dopaminergic receptor is the best investigated and the most useful target for an effective therapy. However, a more specific modulation, stimulation or blockade of these receptors, could strongly reduce the occurrence of the side-effects and the drug resistance that are to be seen after a dopamine substitution started too early or too vigorously.
D000109:Acetylcholine / Q000378:metabolism; D000978:Antiparkinson Agents / Q000378:metabolism / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D018377:Neurotransmitter Agents / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism
D000978:Antiparkinson Agents; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D007980:Levodopa; D000109:Acetylcholine; D004298:Dopamine
Problemen en toekomstperspectieven bij de behandeling van de ziekte van Parkinson.